Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

255
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
255
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

203
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
203
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

609
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
609
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

97
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
97
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches01:14

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

406
Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
406
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

269
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
269

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fear of Cancer Recurrence Among Parents of Children with Cancer Who Underwent Germline Genetic Testing.

Current oncology (Toronto, Ont.)·2026
Same author

Implementation of an Early Mobility Initiative in a Pediatric Bone Marrow Transplant Unit.

Pediatric reports·2025
Same author

ESFT13: A Phase II Study Evaluating the Addition of Window and Maintenance Therapy to a Standard Chemotherapy Backbone for the Treatment of High-Risk Ewing Sarcoma.

Cancers·2025
Same author

A semi-mechanistic dose-finding design in oncology using pharmacokinetic/pharmacodynamic modeling.

Pharmaceutical statistics·2022
Same author

Bayesian single-arm phase II trial designs with time-to-event endpoints.

Pharmaceutical statistics·2021
Same author

A Bayesian adaptive phase I/II platform trial design for pediatric immunotherapy trials.

Statistics in medicine·2020
Same journal

A Bayesian Optimal Interval Design Considering Efficacy and Toxicity in Early Phase Basket Trials.

Pharmaceutical statistics·2026
Same journal

Impact of Information Leakage in Platform Trials With Survival Endpoints on Type I Error Control.

Pharmaceutical statistics·2026
Same journal

Harmonic Fowlkes-Mallows Index for Medical Diagnostics Tests and Optimal Cut-Off Point Selection of Binary Diseases.

Pharmaceutical statistics·2026
Same journal

Early Phase Dose-Finding Designs for CAR-T Cell Therapies.

Pharmaceutical statistics·2026
Same journal

Optimizing Randomization Ratios in Clinical Trials With Survival Endpoints.

Pharmaceutical statistics·2026
Same journal

CUI-MET: A Clinical Utility Index Based Analysis and Decision Framework for Dose Optimization in Multiple-Dose, Multiple-Outcome Randomized Trials.

Pharmaceutical statistics·2026
See all related articles

Related Experiment Video

Updated: Dec 25, 2025

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

19.4K

Bayesian adaptive linearization method for phase I drug combination trials with dimension reduction.

Haitao Pan1, Cheng Cheng1, Ying Yuan2

  • 1Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

Pharmaceutical Statistics
|April 6, 2020
PubMed
Summary
This summary is machine-generated.

This study introduces the Bayesian adaptive linearization method (BALM) for phase I drug combination trials. BALM simplifies finding the maximum tolerated combination (MTC) by reducing dimensions, outperforming complex existing designs.

Keywords:
Bayesian adaptive designdose insertionmaximum tolerated combinationphase I combination trials

More Related Videos

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

470
Development of an Individual-Tree Basal Area Increment Model using a Linear Mixed-Effects Approach
04:35

Development of an Individual-Tree Basal Area Increment Model using a Linear Mixed-Effects Approach

Published on: July 3, 2020

3.6K

Related Experiment Videos

Last Updated: Dec 25, 2025

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

19.4K
Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

470
Development of an Individual-Tree Basal Area Increment Model using a Linear Mixed-Effects Approach
04:35

Development of an Individual-Tree Basal Area Increment Model using a Linear Mixed-Effects Approach

Published on: July 3, 2020

3.6K

Area of Science:

  • * Oncology
  • * Clinical Trials
  • * Pharmacology

Background:

  • * Phase I clinical trials aim to identify the maximum tolerated dose (MTD) or combination (MTC).
  • * Traditional drug combination trials face complexity due to their two-dimensional nature, hindering practical application.
  • * Existing methods often involve intricate statistical modeling and estimation challenges.

Purpose of the Study:

  • * To introduce a simplified, easy-to-implement Bayesian phase I design for drug combination trials.
  • * To address the complexity of two-dimensional dose-finding by employing a dimension reduction approach.
  • * To facilitate the identification of the maximum tolerated combination (MTC) using existing single-agent methods.

Main Methods:

  • * Proposed the Bayesian adaptive linearization method (BALM) for phase I drug combination trials.
  • * Implemented a dimension reduction technique called linearization to order combinations by toxicity.
  • * Incorporated a dose-insertion procedure to add doses targeting the desired toxicity rate if the MTC is not on the selected path.

Main Results:

  • * Simulation studies demonstrated that BALM performs favorably compared to existing complex combination designs.
  • * The linearization process effectively converts the two-dimensional dose matrix into an ordered toxicity string.
  • * BALM simplifies the process of finding the MTC in drug combination studies.

Conclusions:

  • * BALM offers a practical and efficient approach to dose finding in phase I drug combination trials.
  • * The dimension reduction strategy simplifies complex trial designs, making them more accessible.
  • * BALM shows superior performance over more complicated methods in simulations, suggesting its clinical utility.